Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses

NCT04108936 · tracked via the Priya Life Science Germany tracker

Sponsor

University of Regensburg

Phase

Observational

Started

2016-10

Last updated

2022-08-23

Condition(s) studied

Peritoneal Carcinomatosis

Study summary

Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * suspicious peritoneal carcinomatosis Exclusion Criteria: * \<18 years

Primary outcome measure(s)

Disease free survival — Through study completion, an average of 3 years
Prospective analysis of disease free after CRS/HIPEC for peritoneal carcinomatosis
Overall survival — Through study completion, an average of 3 years
Prospective analysis of overall survival after CRS/HIPEC for peritoneal carcinomatosis

Trial sites (2)

Facility	City	Region	Status
Krankenhaus der Barmherzigen Brüder Regensburg	Regensburg	Bavaria	Not Yet Recruiting
University Hospital Regensburg	Regensburg	Germany	Recruiting

More University of Regensburg trials in Germany

Accelerated Treatment of Depressive Patients With tDCS Recruiting

Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment Active, not recruiting

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia Active, not recruiting

Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE Active, not recruiting

Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons Recruiting

Other trials for the same condition

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors Active, not recruiting

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04108936 on ClinicalTrials.gov ↗ ← All trials in Germany